Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Haleon PLC ( (GB:HLN) ) just unveiled an announcement.
Haleon plc has disclosed share transactions by senior executives in line with UK Market Abuse Regulation requirements, confirming that General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers each acquired 34 partnership shares and received 34 matching shares under the company’s Share Reward Plan. The transactions, conducted on 5 January 2026 on the London Stock Exchange, reinforce equity-based alignment between key management and shareholders, signalling continued use of share-based incentives to tie leadership remuneration to the company’s long-term performance.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £440.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects strong financial performance and positive corporate events, which are the most significant factors. Technical analysis and valuation present a more mixed outlook, with some short-term challenges. The earnings call highlights regional strengths but also points to challenges in North America. Overall, the company is well-positioned for future growth, but careful management of liabilities and strategic initiatives will be crucial.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon plc (LSE/NYSE: HLN) is a global consumer health company focused on delivering everyday health products across six categories: oral health, vitamins, minerals and supplements, pain relief, respiratory health, digestive health, and therapeutic skin health and other. Its portfolio includes long-established brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, underpinned by scientific research, innovation and a focus on consumer needs.
Average Trading Volume: 18,824,988
Technical Sentiment Signal: Strong Buy
Current Market Cap: £33.16B
For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.